Reported results
- Research and development expenses were $4.9 million for the three months ended September 30, 2026.
- General and administrative expenses were $2.3 million for the three months ended September 30, 2026.
- Net loss was $15.6 million, or $0.11 per ordinary share (basic and diluted), for the three months ended September 30, 2026.
- Cash and cash equivalents were $265.9 million as of September 30, 2026.
- Restricted cash was $6.5 million as of September 30, 2026.
Guidance
- Entera is preparing to activate the first clinical site for the Phase 3 study in late 2026.
- Topline results for the Phase 3 study are anticipated in the second half of 2028.
- Entera plans to initiate a Phase 1 single ascending dose (SAD) study for EB612 in 2027.
Notes
Net loss for the period was impacted by a $7.5 million non-cash fair value remeasurement of pre-funded warrants.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-06 (8-K, Item 2.02). Read the original filing on sec.gov.
